Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Characterization of grlA, grlB, gyrA, and gyrB Mutations in 116 Unrelated Isolates of Staphylococcus aureus and Effects of Mutations on Ciprofloxacin MIC

Franz-Josef Schmitz, Mark E. Jones, Basia Hofmann, Birgit Hansen, Sibylle Scheuring, Marc Lückefahr, Ad Fluit, Jan Verhoef, Ulrich Hadding, Hans-Peter Heinz, Karl Köhrer
Franz-Josef Schmitz
Institute for Medical Microbiology and Virology and
Eijkman-Winkler Institute for Medical Microbiology, Utrecht University, Utrecht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark E. Jones
Eijkman-Winkler Institute for Medical Microbiology, Utrecht University, Utrecht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Basia Hofmann
Institute for Medical Microbiology and Virology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgit Hansen
Institute for Medical Microbiology and Virology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sibylle Scheuring
Molekularbiologisches Zentrallabor im Biologisch-Medizinischen Forschungszentrum, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Lückefahr
Institute for Medical Microbiology and Virology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ad Fluit
Eijkman-Winkler Institute for Medical Microbiology, Utrecht University, Utrecht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Verhoef
Eijkman-Winkler Institute for Medical Microbiology, Utrecht University, Utrecht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Hadding
Institute for Medical Microbiology and Virology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Peter Heinz
Institute for Medical Microbiology and Virology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl Köhrer
Molekularbiologisches Zentrallabor im Biologisch-Medizinischen Forschungszentrum, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.42.5.1249
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

One hundred sixteen unrelated clinical isolates ofStaphylococcus aureus (70 ciprofloxacin resistant and 46 ciprofloxacin susceptible) from eight countries were studied for the presence of mutations in the grlA, grlB,gyrA, and gyrB gene loci. Two mutations withingrlA (located at codons 80 and 84) and two mutations withingyrA (located at codons 84 and 88) were clearly associated with ciprofloxacin resistance, although other mutations detected within the four genes studied may also contribute to decreased susceptibility.

Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are a therapeutic challenge due to multiple antibiotic resistance (10). Fluoroquinolones (FQs), of which ciprofloxacin is the most widely used, are broad-spectrum antibiotics with good activity against gram-positive organisms, including both methicillin-sensitiveS. aureus and MRSA. The widespread use of FQs has led to the emergence of FQ-resistant S. aureus, especially among MRSA strains (5). Mutations within norA(20), gyrA, gyrB (6, 8, 18), and grlA (3, 13, 19) have been shown to be associated with FQ resistance in S. aureus.norA encodes a membrane protein which acts as a efflux pump (9, 14). gyrA and gyrB encode subunits of DNA gyrase (2, 11). Strains with mutations ingyrA and gyrB, but without grlAmutations, which confer high-level FQ resistance, can be isolated by single-step selection with FQs for Escherichia coli but not for S. aureus (3), although gyrAmutations have been detected in FQ-resistant clinical isolates ofS. aureus (6, 8, 18). grlA andgrlB encode the structural proteins of DNA topoisomerase IV (4), and mutations in the grlA gene, with or without gyrA mutations, have been described for FQ-resistantS. aureus strains (3, 17). Genetic and biochemical evidence suggests that the primary target site of ciprofloxacin, and probably of other FQs, in S. aureusis DNA topoisomerase IV (1, 7, 13) and not DNA gyrase, as inE. coli and Neisseria gonorrhoeae.

This study aimed to characterize mutations in grlA,grlB, gyrA, and gyrB of 116 unrelatedS. aureus isolates derived from eight countries and to correlate the effects of mutations or combinations of mutations within these genes with ciprofloxacin MICs.

Ninety-three MRSA isolates (67 ciprofloxacin resistant and 26 ciprofloxacin susceptible) and 23 methicillin susceptible S. aureus (MSSA) isolates (3 ciprofloxacin resistant and 20 ciprofloxacin susceptible) were included in this study. EightyS. aureus isolates from patients residing in Germany, collected between 1990 and 1995, and 36 S. aureusisolates from seven other countries (8 from Japan, 8 from Brazil, 6 from Switzerland, 4 from Sri Lanka, 4 from Spain, 3 from the United Kingdom, and 3 from Hungary), collected between 1983 and 1989, were tested. All 116 clinical isolates from different patients were screened for the presence of the mecA andcoa genes by multiplex PCR (16). All isolates were selected on the basis of belonging to different pulsed-field gel electrophoresis types (15).

Ciprofloxacin MICs were derived by using a broth microdilution method according to guidelines recommended by the National Committee for Clinical Laboratory Standards (12).

Based on published sequences for grlA and grlB(19) and gyrA and gyrB(8), the appropriate oligonucleotide primers were selected as follows: for grlA, the 5′ primer 2402-ACTTGAAGATGTTTTAGGTGAT-2423 and the 3′ primer 2942-TTAGGAAATCTTGATGGCAA-2961; for grlB, the 5′ primer 1520-CGATTAAAGCACAACAAGCAAG-1541 and the 3′ primer 1874-CATCAGTCATAATAATTACTC-1894; for gyrA, the 5′ primer 2311-AATGAACAAGGTATGACACC-2330 and the 3′ primer 2514-TACGCGCTTCAGTATAACGC-2533; and forgyrB, the 5′ primer 1400-CAGCGTTAGATGTAGCAAGC-1419 and the 3′ primer 1631-CCGATTCCTGTACCAAATGC-1650.

Four independent PCR amplifications were carried out with a GeneAmp PCR System 2400 (Perkin-Elmer, Weiterstadt, Germany), and all reagents (GeneAmp deoxynucleoside triphosphates, high-fidelityTaq DNA polymerase, and 10 × PCR buffer) were purchased from Perkin-Elmer or Boehringer Mannheim (Mannheim, Germany). To prepare cell lysates for use as template DNA in PCR, approximately 1/10 of a single bacterial colony was picked with a pipette tip and mixed in the PCR amplification mixture, consisting of 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl2, 100 μM deoxynucleoside triphosphates, 3 U of high-fidelity Taq DNA polymerase, and 0.4 μM primers in a final volume of 50 μl. Samples were denatured at 94°C for 10 min, followed by 25 amplification cycles with the following parameters: 94°C for 20 s, 55°C for 20 s, and 72°C for 50 s. A final cycle of 72°C for 5 min was used to fully extend amplicons.

PCR products were purified with a PCR purification kit (Qiagen, Hilden, Germany). PCR-amplified DNA was sequenced by the dye terminator method in both the forward and reverse directions. The reaction was carried out with 50 ng of DNA and 0.1 μmol of primers, by using a Ready Reaction Dye Terminator Cycle Sequencing Kit (Perkin-Elmer) according to the manufacturer’s instructions. The products were resolved and automatically analyzed with a 310 DNA sequencer (Perkin-Elmer).

Sequence data from codon 16 to codon 189 of the grlA gene, from codon 386 to codon 497 of the grlB gene, from codon 70 to codon 121 of the gyrA gene, and from codon 413 to codon 483 of the gyrB gene were obtained for further analysis. Wild-type sequences with no mutations were identified on the basis of being identical to the published sequences of grlA andgrlB (19) and gyrA and gyrB(8). Mutations in these genes were identified by comparison.

The mutations identified are summarized in Table1. Within the grlA gene, 11 single or combination mutations were found in 84 isolates; within thegrlB gene, 9 single or combination mutations were located in 20 isolates; within the gyrA gene, 9 single or combination mutations were found in 90 isolates; and within the gyrBgene, 4 single or combination mutations were found in 46 isolates.

View this table:
  • View inline
  • View popup
Table 1.

Mutations within the grlA, grlB,gyrA, and gyrB genes in 116 clonally unrelated clinical isolates of S. aureus from eight countries

The effect of the three amino acid changes within grlB(Table 2) is unclear, as the MICs of ciprofloxacin for several isolates without these mutations are lower (Table 2).

View this table:
  • View inline
  • View popup
Table 2.

Amino acid changes encoded by mutations in thegrlA, grlB, and gyrA gene locia and corresponding ciprofloxacin MICs

From the correlation of the characterized mutations with the resulting MICs of ciprofloxacin (Table 2), it is clear that all the isolates studied that do not have the grlA mutation Ser-80→Phe are ciprofloxacin susceptible.

All ciprofloxacin-resistant isolates for which MICs were ≥4 μg/ml had the grlA mutation Ser-80→Phe in combination with either a Ser-84→Leu mutation or a Glu-88→Lys mutation within the gyrA gene.

In two isolates a Ser-80→Phe mutation was combined with no mutations in the gyrA gene, resulting in a ciprofloxacin MIC of 2 μg/ml, which, while elevated from a wild-type level, is still below the breakpoint for resistance. These data support the finding that inS. aureus, grlA mutations precedegyrA mutations in the development of resistance to ciprofloxacin (3). However, in contrast, two isolates, each of which had a single mutation in the gyrA gene without a corresponding Ser-80→Phe mutation in grlA, were associated with MICs of ciprofloxacin of 0.25 and 1 μg/ml.

Combinations of single point mutations within the gyrA gene have been shown to be associated with higher ciprofloxacin MICs than single point mutations (18). Similarly, two combinations of single point mutations within grlA, a Glu-84→Val or an Ala-48→Thr mutation in combination with a Ser-80→Phe mutation, were associated with relatively higher ciprofloxacin MICs (range, 64 to 256 μg/ml) than only a single Ser-80→Phe mutation (range, 8 to 128 μg/ml) (Table 2).

However, other factors have some effect on ciprofloxacin resistance, as evidenced, for example, by the fact that in the 47 isolates with a single grlA mutation (Ser-80→Phe) in combination with the Ser-84→Leu mutation in gyrA, 16-fold differences in ciprofloxacin MICs occurred. This implicates additional resistance mechanisms associated with elevated MICs of ciprofloxacin (1, 9, 14).

In summary, our data support previous findings and provide evidence that two mutations within the grlA gene (located at codons 80 and 84), as well as two mutations within the gyrA gene (located at codons 84 and 88), are clearly associated with the development of ciprofloxacin resistance. From 116 unrelated isolates we have found 9 combinations of amino acid changes within in GrlA, GrlB, and GyrA associated with resistance to ciprofloxacin. However, some mutations reported by previous workers (3, 6, 8, 17-19) as associated with ciprofloxacin resistance were not found among these isolates, suggesting that other, unknown mutations are likely to exist. The association of mutations within grlA at codon 48, as well as that of polymorphisms in grlB and gyrB, with increased ciprofloxacin MICs is not known. Sequence data from unrelated clones ofS. aureus isolated from different countries show that some grlA and gyrA mutations are conserved in both MRSA and MSSA.

FOOTNOTES

    • Received 25 August 1997.
    • Returned for modification 18 December 1997.
    • Accepted 25 February 1998.
  • Copyright © 1998 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Blanche F.,
    2. Cameron B.,
    3. Bernard F. X.,
    4. Maton L.,
    5. Manse B.,
    6. Ferrero L.,
    7. Ratet N.,
    8. Lecoq C.,
    9. Goniot A.,
    10. Bisch D.,
    11. Crouzet J.
    Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob. Agents Chemother. 40 1996 2714 2720
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Brockbank S. M. V.,
    2. Barth P. T.
    Cloning, sequencing, and expression of the DNA gyrase genes from Straphylococcus aureus. J. Bacteriol. 175 1993 3269 3277
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Ferrero L.,
    2. Cameron B.,
    3. Crouzet J.
    Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39 1995 1554 1558
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Ferrero L.,
    2. Cameron B.,
    3. Manse B.,
    4. Lagneaux D.,
    5. Crouzet J.,
    6. Famechon A.,
    7. Blanche F.
    Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: primary target of fluoroquinolones. Mol. Microbiol. 13 1994 641 653
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Goldstein, F. W., and J. F. Acar. 1995. Epidemiology of quinolone resistance: Europe and North and South America. Drugs 49(Suppl. 2):36–42.
  6. 6.↵
    1. Goswitz J. J.,
    2. Willard K. E.,
    3. Fashing C. E.,
    4. Peterson L. R.
    Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated DNA sequencing. Antimicrob. Agents Chemother. 36 1992 1166 1169
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Hori S.,
    2. Ohshita Y.,
    3. Utsui Y.,
    4. Hiramatsu K.
    Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 37 1993 2278 2284
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Ito H.,
    2. Yoshida H.,
    3. Bogaki-Shonnai M.,
    4. Niga T.,
    5. Hattori H.,
    6. Nakamura S.
    Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob. Agents Chemother. 38 1994 2014 2023
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Kaatz G. W.,
    2. Seo S. M.
    Inducible norA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 39 1995 2650 2655
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Lyon B. R.,
    2. Skurray R.
    Antimicrobial resistance of Staphylococcus aureus: genetic basis. Microbiol. Rev. 51 1987 88 134
    OpenUrlFREE Full Text
  11. 11.↵
    1. Margerrison E. E. C.,
    2. Hopewell R.,
    3. Fisher L. M.
    Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. J. Bacteriol. 174 1992 1596 1603
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial tests for bacteria that grow aerobically. M7-A2. 1991 National Committee for Clinical Laboratory Standards Villanova, Pa
  13. 13.↵
    1. Ng E. Y.,
    2. Trucksis M.,
    3. Hooper D. C.
    Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40 1996 1881 1888
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Ng E. Y. W.,
    2. Trucksis M.,
    3. Hooper D. C.
    Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. 38 1994 1345 1355
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Schmitz, F. J., M. Steiert, H.-V. Tichy, J. Verhoef, H.-P. Heinz, K. Köhrer, and M. E. Jones. Comparison of six different genotypic methods for the typing of methicillin-resistant Staphylococcus aureusisolates from 11 hospitals in the Düsseldorf area. J. Med. Microbiol. in press.
  16. 16.↵
    1. Schmitz F. J.,
    2. Hofmann B.,
    3. Verhoef J.,
    4. Finken-Eigen M.,
    5. Idel H.,
    6. Hadding U.,
    7. Heinz H.-P.,
    8. Köhrer K.
    Specific information concerning taxonomy, pathogenicity and methicillin resistance of staphylococci obtained by a Multiplex PCR. J. Med. Microbiol. 46 1997 773 778
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Takahata M.,
    2. Yonezawa M.,
    3. Kurose S.,
    4. Futakucki N.,
    5. Matsubara N.,
    6. Watanabe Y.,
    7. Narita H.
    Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 38 1996 543 546
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Takenouchi T.,
    2. Ishii C.,
    3. Sugawara M.,
    4. Tokue Y.,
    5. Ohya S.
    Incidence of various gyrA mutations in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob. Agents Chemother. 39 1995 1414 1418
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Yamagishi J. I.,
    2. Kojima T.,
    3. Oyamada Y.,
    4. Fujimoto K.,
    5. Hattori H.,
    6. Nakumara S.,
    7. Inoue M.
    Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40 1996 1157 1163
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Yoshida H.,
    2. Bogaki M.,
    3. Nakamura S.,
    4. Ubukata K.,
    5. Konno M.
    Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J. Bacteriol. 172 1990 6942 6949
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Characterization of grlA, grlB, gyrA, and gyrB Mutations in 116 Unrelated Isolates of Staphylococcus aureus and Effects of Mutations on Ciprofloxacin MIC
Franz-Josef Schmitz, Mark E. Jones, Basia Hofmann, Birgit Hansen, Sibylle Scheuring, Marc Lückefahr, Ad Fluit, Jan Verhoef, Ulrich Hadding, Hans-Peter Heinz, Karl Köhrer
Antimicrobial Agents and Chemotherapy May 1998, 42 (5) 1249-1252; DOI: 10.1128/AAC.42.5.1249

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of grlA, grlB, gyrA, and gyrB Mutations in 116 Unrelated Isolates of Staphylococcus aureus and Effects of Mutations on Ciprofloxacin MIC
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Characterization of grlA, grlB, gyrA, and gyrB Mutations in 116 Unrelated Isolates of Staphylococcus aureus and Effects of Mutations on Ciprofloxacin MIC
Franz-Josef Schmitz, Mark E. Jones, Basia Hofmann, Birgit Hansen, Sibylle Scheuring, Marc Lückefahr, Ad Fluit, Jan Verhoef, Ulrich Hadding, Hans-Peter Heinz, Karl Köhrer
Antimicrobial Agents and Chemotherapy May 1998, 42 (5) 1249-1252; DOI: 10.1128/AAC.42.5.1249
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

anti-infective agents
ciprofloxacin
Genes, Bacterial
mutation
Staphylococcus aureus

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596